QuidelOrtho to Sell Testing Unit in $1.5B Deal, FT Reports
QuidelOrtho is planning to divest a testing unit for $1.5 billion, according to a Financial Times report.
QuidelOrtho is moving to offload one of its testing units in a deal valued at approximately $1.5 billion, the Financial Times reported, marking a significant strategic shift for the diagnostics company as it looks to streamline its portfolio and sharpen its competitive focus.
The planned divestiture signals that QuidelOrtho's leadership is prioritizing capital reallocation, a move that analysts often interpret as an effort to reduce debt, fund core operations, or return value to shareholders. Asset sales of this scale in the diagnostics sector frequently draw attention from private equity buyers and larger strategic acquirers looking to expand their testing capabilities.
Read more Apple Lobbies White House to Buy Chips From Blacklisted Chinese Firm →
QuidelOrtho has faced a challenging post-pandemic landscape, as demand for rapid COVID-19 tests — once a primary revenue driver — has normalized substantially from its peak levels. Divesting a unit at a $1.5 billion valuation could provide the company with meaningful financial flexibility to navigate that transition and invest in higher-growth segments of its business.
The diagnostics industry broadly has been undergoing consolidation, and a deal of this size would rank among the more notable transactions in the sector this year. Further details about the identity of the buyer or the specific business unit involved had not been publicly confirmed at the time of reporting.
Continue reading at SeekingAlpha.
